Sign in or create an account to add this stock to your watchlist.
About Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-12-3544-3939
Debt
Debt-to-Equity RatioN/A
Current Ratio1.89
Quick Ratio1.89
Price-To-Earnings
Trailing P/E Ratio-17.56
Forward P/E Ratio-5.35
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.07 million
Price / Sales5.05
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book14.16
Profitability
EPS (Most Recent Fiscal Year)($0.75)
Net Income$-9,280,000.00
Net Margins-30.89%
Return on Equity-146.46%
Return on Assets-18.23%
Miscellaneous
Employees40
Outstanding Shares13,840,000
Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions
What is Summit Therapeutics' stock symbol?
Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."
How were Summit Therapeutics' earnings last quarter?
Summit Therapeutics (NASDAQ:SMMT) issued its quarterly earnings results on Wednesday, April, 11th. The company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.34. The business earned $4.27 million during the quarter, compared to analyst estimates of $4.91 million. Summit Therapeutics had a negative return on equity of 146.46% and a negative net margin of 30.89%. View Summit Therapeutics' Earnings History.
When is Summit Therapeutics' next earnings date?
What price target have analysts set for SMMT?
7 brokers have issued 1 year price targets for Summit Therapeutics' stock. Their predictions range from $20.00 to $33.00. On average, they anticipate Summit Therapeutics' share price to reach $27.00 in the next year. View Analyst Ratings for Summit Therapeutics.
Who are some of Summit Therapeutics' key competitors?
Some companies that are related to Summit Therapeutics include Dicerna Pharmaceuticals (DRNA), CymaBay Therapeutics (CBAY), Arcus Biosciences (RCUS), Dova Pharmaceuticals (DOVA), Aduro BioTech (ADRO), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Ziopharm Oncology (ZIOP), ChemoCentryx (CCXI), Odonate Therapeutics (ODT), Lannett (LCI), BeyondSpring (BYSI), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML) and Prothena (PRTA).
Who are Summit Therapeutics' key executives?
Summit Therapeutics' management team includes the folowing people:
- Mr. Glyn O. Edwards MBE, Chief Exec. Officer and Exec. Director (Age 62)
- Mr. Erik Ostrowski, Chief Financial Officer (Age 45)
- Prof. Kay Davies FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)
- Prof. David Roblin BSc, MBBS, FRCP, MFPM, Chief Operating Officer, Chief Medical Officer and Pres of R&D (Age 51)
- Ms. Michelle Avery, Director of Investor Relations
When did Summit Therapeutics IPO?
(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.
Has Summit Therapeutics been receiving favorable news coverage?
Headlines about SMMT stock have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Summit Therapeutics earned a news sentiment score of 0.22 on Accern's scale. They also gave news articles about the company an impact score of 48.29 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Summit Therapeutics' major shareholders?
Summit Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (5.42%), Millennium Management LLC (0.17%) and Royal Bank of Canada (0.09%). View Institutional Ownership Trends for Summit Therapeutics.
Which institutional investors are selling Summit Therapeutics stock?
Which institutional investors are buying Summit Therapeutics stock?
How do I buy shares of Summit Therapeutics?
Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Summit Therapeutics' stock price today?
One share of SMMT stock can currently be purchased for approximately $13.17.
How big of a company is Summit Therapeutics?
Summit Therapeutics has a market capitalization of $183.02 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Summit Therapeutics employs 40 workers across the globe.
How can I contact Summit Therapeutics?
Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX14 4RY. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]
MarketBeat Community Rating for Summit Therapeutics (SMMT)
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Summit Therapeutics (NASDAQ:SMMT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Summit Therapeutics in the last 12 months. Their average twelve-month price target is $27.00, suggesting that the stock has a possible upside of 105.01%. The high price target for SMMT is $33.00 and the low price target for SMMT is $20.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.00 | $27.00 | $26.20 | $26.00 |
| Price Target Upside: | 105.01% upside | 104.08% upside | 142.59% upside | 114.34% upside |
Summit Therapeutics (NASDAQ:SMMT) Consensus Price Target History
Summit Therapeutics (NASDAQ:SMMT) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Summit Therapeutics (NASDAQ:SMMT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Summit Therapeutics (NASDAQ SMMT) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 28.13%
Summit Therapeutics (NASDAQ SMMT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Summit Therapeutics (NASDAQ SMMT) News Headlines
| Source: |
|
Summit Therapeutics (NASDAQ:SMMT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Summit Therapeutics (NASDAQ:SMMT) Income Statement, Balance Sheet and Cash Flow Statement
Summit Therapeutics (NASDAQ SMMT) Stock Chart for Saturday, May, 26, 2018
Loading chart…
